Spironolactone Use in Chronic Kidney Disease
Introduction to Spironolactone Dosage Adjustment
- The American College of Cardiology recommends that spironolactone should be avoided in patients with significant CKD (eGFR <30 mL/min/1.73m²) due to high risk of hyperkalemia, and in patients with eGFR between 30-50 mL/min/1.73m², initiate at a reduced dose of 12.5 mg daily or 25 mg every other day with close monitoring 1, 2
Dosing Recommendations Based on Renal Function
- For patients with moderate renal impairment (eGFR 30-50 mL/min/1.73m²), the initial dose should be 25 mg every other day or 12.5 mg daily, with a higher risk of hyperkalemia requiring a more cautious approach 2, 3
- Spironolactone should be avoided in patients with severe renal impairment (eGFR <30 mL/min/1.73m²) due to significantly increased risk of hyperkalemia 1, 2, 4
Monitoring Protocol for Patients with CKD
- Before initiation of spironolactone, verify baseline serum potassium <5.0 mEq/L and assess baseline renal function, and discontinue potassium supplements 2, 3, 4
- After initiation, check serum potassium and renal function at 3 days and 1 week, and continue monitoring at least monthly for the first 3 months 2, 3, 4
Management of Hyperkalemia
- If potassium rises to 5.5-5.9 mEq/L, reduce the dose to 25 mg every other day or 12.5 mg daily, and recheck potassium within 1 week 5
- If potassium ≥6.0 mEq/L, discontinue spironolactone immediately and implement specific treatment for hyperkalemia as needed 5
Risk Factors for Hyperkalemia with Spironolactone in CKD
- Concomitant use of ACE inhibitors or ARBs, especially at higher doses, is a risk factor for hyperkalemia 2
- Baseline potassium ≥5.0 mEq/L, diabetes mellitus, use of NSAIDs or COX-2 inhibitors, and concurrent use of other potassium-sparing diuretics are also risk factors for hyperkalemia 1, 2, 4